PHILADELPHIA, PA, Verismo Therapeutics, a clinical-stage CAR T cell therapy company, announced a $28 million investment from its parent company, HLB Innovation.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.